Navigation Links
Asymmetrex Leads OCTNE 2019 Discussion of the Growing Need for Tissue Stem Cell-Specific Dosing In Stem Cell Clinical Trials

Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials New England in Boston, October 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important design factors that currently limit the success of early stage stem cell clinical trials. To an attendee audience including both developers and suppliers of clinical trials, in his talk Dr. Sherley focused on the highly problematic practice of conducting stem cell clinical trials and stem cell treatments without knowing stem cell dose. He referred to the widespread lack of stem cell-specific dosing as “the major unacknowledged design feature that currently limits the success of ALL stem cell clinical trials.”

As for all effective medicines, stem cells are no different when it comes to the importance of knowing the dose. Sherley pointed out that, without knowing the dose of administered stem cells, it is impossible to interpret the outcome of current clinical trials. With an audience including manufacturers and suppliers of stem cell treatments for clinical trials, Sherley emphasized that the stem cell-specific counting problem extended to many aspects of producing and certifying the quality of tissue stem cell treatment preparations. In the case of manufacturing processes that aim to expand the number of tissue stem cells, some products may have diluted the stem cells to a negligible number and an ineffective dose.

Sherley also shared with attendees that change was now on the horizon of the regulatory landscape for stem cell-specific dosing. With the motivation of Asymmetrex’s new AlphaSTEM Test™ technology, which now makes specific and accurate counting of therapeutic tissue stem cells possible, earlier this year the FDA’s Standards Coordinating Body for Regenerative Medicine (SCB) listed stem cell-specific dose determination as a priority for the development needed standards to advance cellular therapies. Sherley notes, “This was a critical milestone for catching up stem cell medicine to being quantitative, like all the rest of medicine. If the FDA is going to regulate stem cells like other medicines, now that a counting technology is available, they should also guide this industry to its inevitable adoption of dose, a universally acknowledged, fundamental requirement for progress and success in medicine.”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Asymmetrex Article for Parent’s Guide to Cord Blood Describes New Solution for the Stem Cell Counting Problem
2. Asymmetrex Intensifies Campaign to Increase Awareness of the Adult Tissue Stem Cell Counting Problem
3. Asymmetrex Starts New Campaign for Greater Awareness of the Importance of Counting Tissue Stem Cells
4. Asymmetrex Introduces New Contract Service For Producing Greater Numbers of Therapeutic Adult Tissue Stem Cells at Reduced Cost
5. Asymmetrex’s New Patent Issued for Counting and Evaluating Therapeutic Adult Tissue Stem Cells Also Supports Company’s New Stem Cell Production Services
6. Asymmetrex Will Join RegMedNet Panel to Discuss New Developments in Regulatory Policies for Stem Cell Medical Research
7. Asymmetrex Director Comments on Positive Attributes of Private Stem Cell Clinics
8. Asymmetrex Named One of the "50 Most Valuable Brands of the Year 2017" by The Silicon Review
9. Asymmetrex Presents Adult Tissue Stem Cell Counting at the Alliance for Regenerative Medicine’s First Partnering Conference, May 22-23
10. At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific Quality Control Test for Therapeutic Tissue Stem Cells
11. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
Post Your Comments:
(Date:1/28/2020)... ... January 28, 2020 , ... ... R&D, today announced the release of Genedata Expressionist ® 13.5 at ... implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of ...
(Date:1/24/2020)... ... January 24, 2020 , ... ... by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first ... people around the world. And as Slone Partners celebrates its 20th ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO ... of Genome editing. The partners have agreed to co-develop and market a portfolio ... agricultural, and pre-clinical programs. Over the longer-term, the parties aim to develop a ...
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet ... achieve specific properties for use in harsh environments inside or outside of the ... to three metals or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, ...
Breaking Biology Technology:
(Date:2/11/2020)... ... February 11, 2020 , ... ... announce it achieved its ISO 9001:2015 registration by certification body Intertek. Modality Solutions’ ... she reviewed and revised all existing Standard Operating Procedures (SOPs) and created ten ...
(Date:2/10/2020)... ... 2020 , ... A Worcester Polytechnic Institute (WPI) bioinformatics researcher ... a major development that potentially holds the key to understanding the spread and ... the Wuhan coronavirus made available on the National Center for Biotechnology Information ...
(Date:2/6/2020)... ... February 06, 2020 , ... ... to unique lab-made bioresearch materials, today announced an agreement with The Good ... and seafood a reality. Under the partnership, terrestrial meat and aquatic cell lines ...
Breaking Biology News(10 mins):